Wednesday, November 26, 2014
Inquirer Daily News

Now FDA must act on GSK's Avandia

Food and Drug Administration advisory panel voted 20 to 12 Wednesday to keep GlaxoSmithKline's controversial diabetes drug Avandia on the market in the U.S., albeit recommending with stronger warnings about the increase risk of heart attacks, heart failure and stroke for those taking the medication.

Now FDA must act on GSK’s Avandia

A Food and Drug Administration advisory panel voted 20 to 12 Wednesday to keep GlaxoSmithKline’s controversial diabetes drug Avandia on the market in the U.S., albeit recommending with stronger warnings about the increase risk of heart attacks, heart failure and stroke for those taking the medication.

Before the vote on whether or not to take Avandia off the market here, the panel had voted 21 to 4 that the medication increased the risk of heart attacks compared with other medications used to treat diabetes including the competing drug Actos by made by a Japanese pharmaceutical company.

The FDA will now decide on what action if any to take in regards to Avandia. The drug agency is not required to follow the advice of the advisory panel, but usually does. Here's the full story on Wednesday's advisory committee actions.

To check out more Check Up items go to www.philly.com/checkup.

About this blog

Check Up covers major health events in our region and offers everything from personal health advice to an expert look at health reform. Read about some of our bloggers here.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section

Michael R. Cohen, R.Ph. President, Institute for Safe Medication Practices
Daniel R. Hoffman, Ph.D. President, Pharmaceutical Business Research Associates
Latest Health Videos
Also on Philly.com:
Stay Connected